Obsidian and Galera Therapeutics have completed a reverse merger to form a combined entity focused on advancing a pipeline of cell therapies. The new company will trade on the Nasdaq under the ticker symbol OBX. This strategic move is designed to accelerate the development of their core therapeutic programs.
A concurrent private placement has secured commitments for $350 million in gross proceeds. This substantial capital infusion is earmarked for funding clinical trials and advancing the firm's research platform. The financing underscores investor confidence in the merged company's scientific approach and its potential to address unmet medical needs.